Indegene Limited IPO : Review & Complete Analysis

Indegene Limited IPO date is slated to be open for subscription from May 6, 2024, to May 8, 2024. This NSE, BSE IPO follows a Book Built Issue IPO. Indegene Limited IPO price is fixed in the range of at Rs.430 to Rs.452 per share. The total issue size of this IPO amounts to Rs.1,841.76 Cr. The company has allocated shares 35% to retail investors, 50% to institutional and 15% to non instituional investors.

May 3, 2024 - 19:14

0 25

Indegene Limited IPO

Indegene Limited, a leader in digital-led commercialization services for the life sciences industry, is set to launch its IPO. Here's a comprehensive overview of the company and its IPO:

Company Overview:

Established in 1998, Indegene Limited offers a range of services to the life sciences industry, including drug development, clinical trials, regulatory submissions, and sales and marketing. With a focus on digital solutions, the company empowers clients to develop and launch products more effectively, driving sales throughout their lifecycle. It serves biopharmaceutical, emerging biotech, and medical devices companies globally.

Financial Performance:

Indegene Limited has demonstrated robust financial performance, with growth in total assets, net worth, total revenue, and profit after tax. The company's strong financials indicate its stability and potential for further expansion.

Strengths and Weaknesses:

The company's strengths include domain expertise in healthcare, robust digital capabilities, a track record of long-standing client relationships, a global delivery model, and an experienced management team. However, challenges such as industry-related risks, revenue concentration from subsidiaries, and compliance requirements pose potential weaknesses.

IPO Details:

The IPO is scheduled from May 6 to May 8, 2024, with a price range of Rs. 430 to Rs. 452 per share. The issue size amounts to Rs. 1,841.76 crore, with shares allocated to retail, institutional, and non-institutional investors. The company plans to utilize the proceeds for debt repayment, capital expenditure, and general corporate purposes.